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Key Points  50 
Question: Can therapeutic drug monitoring for the IL-12/23 inhibitor ustekinumab optimise 51 
treatment pathways and outcomes in psoriasis? 52 
Findings: Early serum ustekinumab levels predicted subsequent PASI75 response, although 53 
this relationship did not hold across other PASI outcomes. Drug immunogenicity appeared 54 
low, with anti-drug antibodies detected in only 3.5% of patients.  55 
Meaning: This real-world study provides evidence that measurement of early ustekinumab 56 
levels could be useful to direct treatment strategy in psoriasis. Adequate drug exposure 57 
early in the treatment cycle may be particularly important in determining clinical outcome. 58 
 59 
60 
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Abbreviations 61 
 62 
ADA - Anti-drug antibodies  63 
AIC - Akaike Information Criterion  64 
AU – Arbitrary units 65 
BADBIR - British Association of Dermatologists Biologic Interventions Registry  66 
BMI – Body mass index 67 
BSTOP - Biomarkers of Systemic Treatment Outcomes in Psoriasis  68 
CI - Confidence interval  69 
IL - Interleukin 70 
OR - Odds ratio  71 
PASI - Psoriasis Area and Severity Index  72 
PSORTD – Psoriasis Stratification to Optimise Relevant Therapy (Discovery) 73 
SD – standard deviation 74 
TDM – Therapeutic drug monitoring 75 
TNF - tumour necrosis factor  76 
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Abstract  78 
Importance: High-cost biologic therapies have transformed the management of immune-79 
mediated inflammatory diseases. To optimise outcomes and reduce costs, dose adjustment 80 
informed by circulating drug levels has been shown to be effective in various settings. 81 
However, limited evidence exists for this approach with the IL-12/23 inhibitor ustekinumab.  82 
Objective: To determine the real-world clinical utility of therapeutic drug monitoring in 83 
psoriasis for ustekinumab. 84 
Design: A prospective observational cohort of adults recruited to Biomarkers of Systemic 85 
Treatment Outcomes in Psoriasis within the British Association of Dermatologists Biologic 86 
and Immunomodulators Register, 2009-2017. 87 
Setting: Multicenter (n=60) UK and Eire study; dermatology secondary care. 88 
Participants: Adults with psoriasis, started on ustekinumab with up to one year’s follow-up.  89 
Exposure: Serum ustekinumab level (µg/ml), measured at any point during the dosing cycle 90 
using an enzyme-linked immunosorbent assay. 91 
Main Outcomes and Measures: Disease activity measured using the Psoriasis Area and 92 
Severity Index (PASI). Treatment response outcomes were PASI75 (75% reduction in PASI 93 
from baseline, primary outcome), PASI90 and absolute PASI≤1.5.  94 
Results: 491 patients (65.2% male; mean age 45.7 years (sd 12.8)) had >1 serum sample 95 
(total 853 samples taken 0-56 weeks from start of treatment) and >1 PASI score within the 96 
first year of treatment. Anti-drug antibodies were detected in only 3.5% of patients. Early 97 
drug levels (1-12 weeks after starting treatment) were predictive of PASI75 response 6 98 
months after starting treatment (OR 1.38, 95% CI 1.11-1.71) when adjusted for baseline 99 
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PASI, age and ustekinumab dose. However, this was not consistent across the other PASI 100 
outcomes (PASI90 and PASI≤1.5).    101 
Conclusions and Relevance: This real-world study provides evidence that measurement of 102 
early serum ustekinumab levels could be useful to direct treatment strategy in psoriasis. 103 
Adequate drug exposure early in the treatment cycle may be particularly important in 104 
determining clinical outcome.  105 
  106 
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Introduction  107 
Psoriasis is a chronic immune-mediated skin disease affecting at least 2% of the population1. 108 
Management has been transformed by therapeutic monoclonal antibody biologics, of which 109 
the first-line choices are either adalimumab (a tumour necrosis factor [TNF] inhibitor) or 110 
ustekinumab (an interleukin [IL]-12/IL-23 inhibitor)2. There is wide variation in response to 111 
these drugs, with a significant number of patients not responding (primary treatment 112 
failure) or losing response over time (secondary treatment failure)3,4. Some of this 113 
heterogeneity may be explained by differences in the bioavailability and quantity of drug 114 
available at the target tissue, which in turn is influenced by adherence, drug dose and 115 
pharmacokinetic covariates such as weight and drug immunogenicity (development of anti-116 
drug antibodies [ADA]).  117 
   Unlike most other biologics used for inflammatory disease, ustekinumab is dosed 118 
according to bodyweight; patients under 100kg are generally given 45mg subcutaneously 119 
every 12 weeks, whereas those weighing at least 100kg are given 90mg5. Despite this, 120 
evidence suggests that ustekinumab dosing is suboptimal in some patients: clinical trial data 121 
previously showed that dose escalation increased PASI75 response rates in partial 122 
responders (those achieving > or =50% but <75% improvement from baseline PASI)6, whilst 123 
patients with higher baseline body mass index (BMI) have been reported to receive in 124 
excess of the recommended cumulative dose over the first year of treatment7. Similarly, 125 
response rates to ustekinumab in patients weighing 90-100kg have been reported to be 126 
significantly lower than in other weight groups, suggesting that the standard 45mg dose is 127 
inadequate in patients approaching the 100kg threshold8. On the other hand, ustekinumab 128 
dosing is likely to be excessive in some patients; a recent phase IIIb study reported that 129 
lengthening intervals between ustekinumab doses did not affect maintenance of response9.  130 
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Taken together, these findings suggest that individualized dose optimization and 131 
therapeutic drug monitoring (TDM) of ustekinumab may have clinical utility. 132 
   Although several ustekinumab assays are commercially available in both the USA and 133 
Europe10-15, serum ustekinumab levels are not yet widely used in clinical practice. This is 134 
partly due to limited evidence for TDM of this drug, in contrast to the strong correlation 135 
described between TNF inhibitor serum levels, ADA and treatment response across multiple 136 
immune-mediated inflammatory diseases16-20. Indeed, reports on the relationship between 137 
ustekinumab level and response have been inconclusive21-25, with basic parameter 138 
requirements for TDM (eg. therapeutic range, target drug level) yet to be established in the 139 
context of psoriasis.  140 
   Since the first step towards defining such parameters is to determine the relationship 141 
between drug levels and outcome, we investigated this using a real-world bioresource from 142 
a large multicenter cohort study BSTOP (Biomarkers of Systemic Treatment Outcomes in 143 
Psoriasis) within the UK pharmacovigilance registry BADBIR (British Association of 144 
Dermatologists Biologic and Immunomodulators Register). Specifically, we aimed to (1) 145 
explore the relationship between drug level and response on the same day the drug level 146 
was taken, and (2) explore the relationship between early drug level and response at 6 147 
months, since maximum clinical utility may lie in the ability to predict outcome and modify 148 
therapy prior to clinical relapse.   149 
  150 
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Materials and methods 151 
Ethics approval 152 
This study was conducted in accordance with the 2008 Declaration of Helsinki.  Two studies 153 
provided samples and data: BSTOP (ethics approval code 11/H0802/7), and its nested study 154 
Psoriasis Stratification to Optimise Relevant Therapy Discovery (PSORTD, ethics approval 155 
code 14/LO/1685).  156 
Patients and setting 157 
As described previously20, BSTOP is a prospective multicenter (n=60) observational study, 158 
established in 2011 to identify markers of outcomes to systemic therapies in psoriasis. All 159 
UK adults fulfilling BSTOP inclusion criteria26 and enrolled onto BADBIR27 were invited to 160 
participate. Clinical response was assessed longitudinally using the Psoriasis Area and 161 
Severity Index (PASI). The current analysis includes patients on ustekinumab monotherapy, 162 
with >1 serum sample and >1 recorded PASI within the first year of treatment (Figure 1).     163 
Drug level and ADA measurements 164 
Venous blood was collected during clinic reviews, centrifuged for 10 minutes (2000g) and 165 
serum aliquots frozen (-80°C). In this pragmatic study, samples were not collected from 166 
every patient at every timepoint; most were taken without reference to treatment 167 
administration. Samples within the first year of treatment were sent to Sanquin for 168 
measurement if ustekinumab levels and ADA. The ustekinumab level assay was an enzyme-169 
linked immunosorbent assay similar to a previously developed adalimumab assay28, but 170 
using IL-12 to capture ustekinumab, with rabbit anti-ustekinumab for detection (lower limit 171 
of detection 0.02µg/mL). ADA were measured using a previously described 172 
radioimmunoassay29, with minor modifications (ADA positive cutoff >12 arbitrary units 173 
[AU]/ml). Specifically, 1µl serum diluted in freeze medium was incubated with Sepharose-174 
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immobilized protein A in the presence of 1ng/test biotin-conjugated ustekinumab F(ab)2. 175 
Non-bound serum components were removed by washing; 50µl 125I-labelled streptavidin 176 
was added in 500µl phosphate buffered saline-albumin tween (0.3% bovine serum albumin, 177 
0.01M ethylenediaminetetraacetic acid, 0.004% tween-20, 0.05% NaN3). After incubation 178 
and washing, radioactivity was measured using a gamma counter. Assay results were 179 
converted to AU/ml calculated from a 2-fold serially diluted calibration curve of a polyclonal 180 
ustekinumab-specific rabbit anti-idiotype30. This assay format has limited drug-tolerance31, 181 
but was previously shown to have better correlation with clinical response versus drug-182 
tolerant alternatives in rheumatoid arthritis patients on adalimumab32.  183 
Outcome measures 184 
Primary treatment response was defined as achieving a 75% reduction in PASI from baseline 185 
(PASI75), with baseline PASI defined as the most recent PASI recorded prior to the date of 186 
the first drug dose within the preceding 6 months3,33. Secondary outcomes were: i) PASI90 187 
(90% PASI reduction from baseline) ii) PASI<1.5 (absolute PASI<1.5, which approximates to 188 
PASI90, personal communication Nina Wilson).  189 
Statistical methods 190 
Based on our previous work using adalimumab drug levels20, we explored the relationship 191 
between ustekinumab level and response in two ways.  First, we investigated the 192 
association between drug levels and response on the same day of the sample; secondly, we 193 
investigated whether drug levels sampled early following treatment start, can predict 194 
response at 6 months. Two datasets were therefore derived: a dataset comprising samples 195 
taken at steady state (≥16 weeks after treatment start), with a corresponding PASI on the 196 
same day as the sample date - hereafter referred to as the ‘same-day response’ dataset; and 197 
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a dataset comprising samples taken early in the treatment course (1-12 weeks after 198 
treatment start), with a corresponding PASI at 6 months (122-243 days after treatment 199 
start) - hereafter referred to as the ‘6-month response’ dataset.  Analyses for PASI75 and 200 
PASI90 responses were restricted to patients with baseline PASI >10 as an accepted criterion 201 
for severe disease34, and to minimize confounding due to pre-biologic treatments. The latter 202 
is particularly relevant in this real-world dataset. 203 
Descriptive analysis 204 
A descriptive concentration effect curve was generated to assess whether clinical response 205 
plateaus beyond a certain drug level. Boxplots were used to visually compare drug levels by 206 
responder group in both the ‘same-day response’ and ‘6-month response’ datasets. 207 
Logistic regression analysis 208 
We used univariate logistic regression models with the `6-month response’ dataset to 209 
explore the relationship between early drug levels and treatment response in the presence 210 
of other covariates, including those previously identified as predictors of response in the 211 
BADBIR cohort (eg. weight, ethnicity, disease/treatment duration, ustekinumab dose, 212 
biologic-naïve status)35. Given that most samples were not trough levels, we also included 213 
time of sample from last ustekinumab dose as a covariate. For continuous covariates, the 214 
best-fitting simple non-linear transformation was chosen based on reduction in the Akaike 215 
Information Criterion (AIC). Covariates associated with response at significance level p<0.1 216 
were taken forward to a multivariable logistic regression model. Forward selection 217 
techniques were then used, with covariate inclusion based on a significance level of p<0.05. 218 
Multivariable models were derived for all three PASI outcomes (PASI75, PASI90 and 219 
PASI<1.5). For PASI90 and PASI<1.5, drug level was included as the first covariate and 220 
retained at each stage, despite not being significant on univariate analysis. Pseudo R2 and 221 
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AIC were calculated to assess model fit. All analyses were undertaken using Stata version 222 
1436 on a complete case basis. 223 
 224 
Results  225 
Patient cohort and baseline characteristics 226 
491 patients on ustekinumab monotherapy had both serum samples and PASI scores 227 
available within the first year of treatment (Figure 1, Table 1). The cohort was 228 
predominantly male (65.2%), with mean BMI 32.0 (sd 7.3) and mean baseline PASI 13.3 (sd 229 
6.8). 40.9% of patients were biologic-naïve, and 57.4% were on 45mg ustekinumab versus 230 
42.6% on 90mg (Table 1). Patients not providing serum samples were excluded, but their 231 
baseline characteristics were similar (eTable 1).  232 
Response to treatment 233 
70.9% of patients (348/491) achieved PASI75 at some point within a year of starting 234 
treatment. PASI75 remains a standard measure of adequate treatment response in UK 235 
guidelines37.  236 
Drug levels and ADA 237 
Drug levels were sampled according to standard clinical care. Excluding samples taken on 238 
the day the first dose was given: the median time from last dose was 28 days (IQR 16-57 239 
days, range 0-98 days, data available on n=515 samples); median drug level was 1.19μg/ml 240 
(IQR 0.37-2.86μg/ml, range 0-13.1μg/ml, n=800 samples); ADA were detected in 3.5% 241 
(17/490) of patients (on 20 samples taken 29-350 days after starting treatment).  242 
Relationship between drug level and response 243 
All analyses considered all eligible samples (maximum 4 per patient). 244 
Descriptive analysis 245 
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A concentration effect curve showed no clear evidence of a relationship between steady 246 
state drug levels and same-day absolute PASI (eFigure 1). Median drug level and spread of 247 
drug levels were similar between patients recorded to have responded/not responded on 248 
the same day as the serum sample was taken (‘same-day response’ dataset, eFigure 2). 249 
However, patients achieving PASI75 at 6 months (‘6-month response’ dataset) on average 250 
had higher early ustekinumab levels (median 2.78μg/ml, IQR 1.78-4.02, range 0.02-9.78) 251 
compared to patients not achieving PASI75 (median 1.83μg/ml, IQR 0.96-2.86, range 0.02-252 
9.00, Figure 2), with overlapping ranges between the two groups. A similar pattern was 253 
observed for the other two response outcomes PASI90 and PASI≤1.5 (eFigure 3).  254 
   To explore the relationship between drug level, response and dose, we split boxplot data 255 
by ustekinumab dose 45mg/90mg (Figure 2b). As expected, PASI75 responders had higher 256 
median drug levels than non-responders within each dose group. This pattern was also 257 
evident for the PASI90 and PASI≤1.5 outcomes (eFigure 4). However, PASI75 non-258 
responders on 90mg ustekinumab had slightly higher median drug levels than non-259 
responders on 45mg, albeit with overlapping ranges and large variability (Figure 2b).  260 
Logistic regression analysis  261 
Univariate logistic regression indicated that early drug level was associated with 6-month 262 
PASI75 (‘6-month response’ dataset: OR 1.27, 95% CI 1.04-1.56), but there was no evidence 263 
of this relationship for the other two PASI outcomes (eTable 2). Next, multivariable models 264 
were derived to explore the relationship between early drug level and 6-month response in 265 
the presence of other relevant covariates. The final model for PASI75 included drug dose, 266 
baseline PASI and age as well as drug level (OR 1.38, 95% CI 1.11-1.71, Table 2), and shows 267 
increasing probability of response with increasing drug level (Figure 3). The model also 268 
suggests that patients on the higher ustekinumab dose (90mg) have a lower probability of 269 
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response for a given drug level (Figure 3). To explore this finding further, we inspected 270 
boxplots of drug levels split by weight and dose (eFigure 5). Despite overlapping ranges, 271 
these show slightly lower median drug levels both in patients weighing >100kg, and in 272 
patients on the higher ustekinumab dose. 273 
   Drug level was non-significant for the PASI90 and PASI<1.5 outcomes, even taking into 274 
account other covariates. Furthermore, significant covariates were not consistent across the 275 
three models for different PASI outcomes within the 6-month response dataset. Finally, we 276 
performed a sensitivity analysis by fitting the final model for PASI75 to very early trough 277 
samples (21-28 days after treatment start). Despite smaller sample size and greater 278 
uncertainty around estimates, a similar relationship between drug level and response was 279 
seen (OR 1.31, 95% CI 1.24-11.08, eTable 3).  280 
 281 
  282 
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Discussion  283 
Key findings 284 
In the largest study to date of ustekinumab drug level monitoring in psoriasis, we report 285 
evidence that early ustekinumab levels were significantly associated with 6-month PASI75 286 
response. This finding has particular clinical and practical relevance, because assays to 287 
measure serum ustekinumab levels are already commercially available in both the USA and 288 
Europe10-15. 289 
   We also report a low rate (3.5%) of detectable ADA to ustekinumab within the first year of 290 
treatment, compared to the previously reported rate of 37.5% in a cohort of patients on 291 
adalimumab derived from the same UK study20. It is possible that this differential drug 292 
immunogenicity accounts, at least partially, for significantly higher rates of drug survival 293 
(length of time from initiation to discontinuation) on ustekinumab compared to 294 
adalimumab3.  295 
   The finding that the higher ustekinumab dose is associated with a lower probability of 296 
response is perhaps surprising. One possible explanation is that patients on the higher dose 297 
exhibit characteristics predictive of poor response, that have not been accounted for in our 298 
model. An alternative explanation may be that a double dose of ustekinumab (90mg as 299 
opposed to 45mg) fails to adequately compensate for the increased volume of distribution 300 
in some people of higher bodyweight; indeed, we noted that median drug levels were 301 
slightly lower both in patients on the higher ustekinumab dose and in patients weighing 302 
>100kg. 303 
   Our dataset should allow for stable estimation of comparable numbers (4-5) of 304 
covariates38 in each of the analyses for early drug level versus the three different PASI 305 
outcomes. However, we were unable to demonstrate a link between early drug level and 306 
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the other PASI outcomes, nor between steady state drug levels and same-day response. It is 307 
therefore possible that the association between early drug level and PASI75 is due to a 308 
spurious p value or statistical artefact. This contrasts with our findings for adalimumab, 309 
where the same statistical approach showed that both early and steady state drug levels 310 
were significantly associated with all PASI outcomes. A fundamental explanation for this 311 
may lie in differing mechanisms of biologic action: adalimumab directly inhibits the 312 
inflammatory effector cytokine TNF, whereas ustekinumab inhibits IL-12 and IL-23 – the 313 
latter being a master regulator of pathogenic T helper 17 cell development39. Just as the 314 
underlying biological impact is more complex for ustekinumab, it may be that the 315 
relationship between drug level and response is correspondingly convoluted.  316 
Existing literature 317 
Other studies in this area are few in number, generally limited to descriptive or empirical 318 
analyses investigating the relationship between ustekinumab level and response, and report 319 
mixed results. The most recent study in psoriasis included prospective follow-up of only 27 320 
patients, but reported similar findings to us, in that very early drug levels (Week 6) were 321 
inversely correlated with subsequent response (Week 12). However, in line with our data, 322 
no relationship was detected between drug levels taken later (in this case at Week 12) and 323 
same-day response25.  324 
   The largest study in psoriasis reported significantly lower drug levels and PASI50 response 325 
rates in patients with detectable ADA compared to those without23. Finally, in a Dutch 326 
cohort of 41 psoriasis patients there was no correlation between ustekinumab level and 327 
response; 7% (3/41) of patients developed ADA24.  328 
   Larger-scale studies have been conducted in the context of inflammatory bowel disease. 329 
Indeed, it is possible that variability in the amount of drug lost via the inflamed gut means 330 
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that some patients are less able to achieve adequate serum concentrations, meaning that 331 
TDM may have greater utility in this setting. An analysis of Phase 3 trial data (n = 1154) 332 
reported positive association of drug levels with clinical and endoscopic improvement, and 333 
inverse correlation with C-reactive protein level. Only 2% of patients developed ADA21.  334 
Strengths and limitations  335 
A strength of this study is high external validity, since more than 50% of all UK psoriasis 336 
patients on biologics are registered on BADBIR, and 95% of UK dermatology centers 337 
prescribing biologics for psoriasis contribute data to BADBIR. Our findings highlight the 338 
potential clinical utility of this easily measurable early biomarker in optimizing subsequent 339 
response. They also serve as a call to action for both industry and academia to develop cost-340 
effective and widely available assays, and to further validate the role of TDM in clinical 341 
practice.   342 
   One limitation is that out of 491 patients with both a serum sample and PASI within a year 343 
of treatment, the ‘same-day response’ and ‘6-month response’ datasets included 148 and 344 
85 patients respectively. Figure 1 shows the drop-off in patient numbers at each stage of 345 
filtering.  346 
   A second limitation relates to the difficulty in accounting for the complex relationship 347 
between drug level and response using a standard logistic regression modelling approach. 348 
This has been successfully used in other settings, notably to define a therapeutic range and 349 
target drug level for adalimumab20. However, it is possible that ustekinumab’s extended 350 
dosing interval compared to adalimumab may pose a particular hindrance in this context, as 351 
a single or small number of drug levels may represent a relatively poor measure of total 352 
drug exposure. This issue may have been exacerbated by pragmatic serum sampling and 353 
PASI assessment at routine clinical visits, as opposed to having samples and PASIs only 354 
 18 
 
 
during trough periods. To partially address this, we accounted for the timing of samples by 355 
including time from last ustekinumab dose as a covariate in modelling, but this did not 356 
remain in the final multivariable models after the forward selection process. Finally, the 357 
validity of our findings is limited to within one year of start of treatment, since this was the 358 
selected cohort duration. 359 
Conclusion 360 
Despite the complexities outlined above, we did find a significant association between early 361 
drug levels (<12 weeks) and 6-month PASI75 response. This suggests that adequate drug 362 
exposure early in the treatment cycle may be particularly important in determining clinical 363 
outcome on ustekinumab. However, our statistical approach did not take into account 364 
patient-level pharmacokinetic parameters such as volume of distribution and clearance, nor 365 
potential differences in the evolution of PASI over time versus changing drug levels. 366 
Therefore, future work should focus on pharmacokinetic-pharmacodynamic modelling of 367 
the whole timecourse of response to ustekinumab40. This may be of particular relevance for 368 
biologics with more upstream targets, such as differentiation pathway cytokines as opposed 369 
to effector cytokines. Further investigation to confirm the clinical utility of TDM of 370 
ustekinumab and other biologics is a key step towards personalisation of treatment 371 
regimens across multiple immune-mediated inflammatory diseases. 372 
  373 
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Table 1. Summary statistics for the full cohort, ‘same-day response’ dataset and ‘6-month 537 
response’ dataset 538 
 539 
 Full cohort  
 
 
(n= 491 patients,  
853 samples) 
‘Same-day 
response’ dataset 
  
(n= 148 patients, 
175 samples) 
‘6-month 
response’ dataset  
 
(n= 85 patients, 
119 samples) 
Covariate Mean 
(sd) 
Complete 
data  
n (%) 
Mean 
(sd) 
Complete 
data  
n (%) 
Mean 
(sd) 
Complete 
data  
n (%) 
Baseline PASI  13.3 
(6.8) 
452 
(92.1) 
16.6 
(5.2) 
148  
(100) 
16.3 
(5.5) 
85  
(100) 
Height (cm) 172.2 
(10.3) 
463 
(94.3) 
172.4 
(10.5) 
140 
(94.6) 
172.1 
(10.5) 
81  
(95.3) 
Weight (kg) 94.7 
(22.7) 
435 
(88.6) 
96.1 
(23.7) 
140 
(94.6) 
94.2 
(22.9) 
80  
(94.1) 
Waist (cm) 105.8 
(16.8) 
420 
(85.5) 
106.5 
(17.4) 
131 
(88.5) 
105.2 
(15.7) 
77  
(90.6) 
BMI (kg/m2) 32.0 
(7.3) 
427 
(87.0) 
32.3 
(7.7) 
136 
(91.9) 
31.7 
(7.6) 
78  
(91.8) 
Age (years) 45.7 
(12.8) 
491  
(100) 
45.2 
(13.1) 
148  
(100) 
48.7 
(13.3) 
85  
(100) 
Disease duration 
(years) 
23.3 
(13.1) 
464 
(94.5) 
23.1 
(13.1) 
142 
(95.9) 
23.4 
(13.0) 
82  
(96.5) 
 n (%)  n (%)  n (%)  
Ethnicity – white 421 491  123 148  70 85  
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(85.7) (100) (83.1) (100) (82.4) (100) 
Gender - male 320 
(65.2) 
491  
(100) 
99 
(66.9) 
148  
(100) 
59 
(69.4) 
85  
(100) 
Inflammatory 
arthritis  
101 
(23.5) 
430 
(87.6) 
26 
(18.8) 
138 
(93.2) 
24 
(30.4) 
79  
(92.9) 
Ever smoked  289 
(61.2) 
472 
(96.1) 
81 
(55.9) 
145 
(98.0) 
51 
(61.5) 
83  
(97.6) 
Palm psoriasis 93 
(21.1) 
441 
(89.8) 
30 
(21.6) 
139 
(93.9) 
19 
(24.1) 
79  
(92.9) 
Biologic naive 201 
(40.9) 
491  
(100) 
64 
(43.2) 
148  
(100) 
37 
(43.5) 
85  
(100) 
Dose  45mg 
            
           90mg 
282 
(57.4) 
209 
(42.6) 
491  
(100) 
82 
(55.4) 
66 
(55.6) 
148  
(100) 
48 
(56.5) 
37 
(43.5) 
85  
(100) 
 540 
Summaries for the ‘same-day response and ‘6-month response’ datasets are restricted to patients with baseline PASI > 10. 541 
 542 
 543 
  544 
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Table 2. Final multivariable models for predicting 6-month response  545 
 546 
 Covariate Coefficient 
(s.e) 
OR  
(95% CI) 
P value Pseudo R2 Number 
of 
samples 
Number of 
responders    
(% of 
samples) 
PASI75  Drug level 
(μg/ml) 
0.32  
(0.11) 
1.38 
 (1.11, 1.71) 
0.004 0.18 119 73  
(61.3) 
Baseline 
PASI 
0.10  
(0.04) 
1.10 
 (1.01, 1.20) 
0.03 
Age (years) 0.04  
(0.02) 
1.04 
 (1.00, 1.07) 
0.03 
Dose 90 mg -1.43  
(0.44) 
0.24 
 (0.10, 0.56) 
0.001 
PASI90  Drug level 
(μg/ml) 
0.14  
(0.09) 
1.15 
 (0.97, 1.38) 
0.1 0.10 115 45  
(39.1) 
Baseline 
PASI 
0.10  
(0.04) 
1.11 
 (1.02, 1.20) 
0.01 
Disease 
duration 
(years) 
0.04  
(0.02) 
1.04 
 (1.01, 1.08) 
0.009 
PASI≤1.5  Drug level 
(μg/ml) 
0.11  
(0.08) 
1.12 
 (0.96, 1.30) 
0.2 0.06 186 58  
(31.2) 
Biologic 
naïve 
0.92  
(0.33) 
2.51 
 (1.31, 4.81) 
0.006 
Ever 
smoked 
-0.70 
(0.34) 
0.50 (0.26, 
0.96) 
0.04 
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FIGURE TITLES AND LEGENDS 547 
 548 
Figure 1. Flow diagram of patients included in the study 549 
 550 
 551 
Figure 2. Boxplots comparing early drug levels by 6-month PASI75 response  552 
a. Split by response only 553 
n = 46 and 73 samples in each group respectively. On each boxplot: middle line is the median, circles are the 554 
means, ends of boxes are the lower and upper quartiles, solid dots are outliers (values more than or equal to 555 
1.5 times the interquartile range from the lower and upper quartiles), whiskers show the minimum and 556 
maximum values (unless there are outliers, in which case they are 1.5 times the interquartile range from the 557 
lower and upper quartiles).  558 
 559 
b. Split by response and by ustekinumab dose 560 
n = 18, 50, 28, 23 samples in each group respectively. The red boxes correspond to 45mg and the blue boxes 561 
correspond to 90mg. On each boxplot: middle line is the median, circles are the means, ends of boxes are the 562 
lower and upper quartiles, solid dots are outliers (values more than or equal to 1.5 times the interquartile 563 
range from the lower and upper quartiles), whiskers show the minimum and maximum values (unless there 564 
are outliers, in which case they are 1.5 times the interquartile range from the lower and upper quartiles). 565 
 566 
 567 
Figure 3. Probability of 6-month PASI75 response based on early drug level, split by ustekinumab dose 568 
Probability of response is split by ustekinumab dose (45 mg in blue, 90 mg in red). Solid lines plot the marginal 569 
predicted probability of response; dashed lines are 95% confidence intervals. 570 
 571 
 572 




